Lawsuit Help Desk

Valsartan Lawsuits and Settlements

Have you taken Valsartan for the treatment of hypertension, and heart related issues? Did you take it for a minimum of one year between 2015 to the present time? Were you diagnosed in 2017 or later with any of these cancers: Stomach, Intestinal, Colorectal, Esophageal, Liver, Prostate (if under age 65), Pancreatic, Leukemia, Non-Hodgkin’s Lymphoma, or Multiple Myeloma? Then there is a real likelihood you would qualify for a Valsartan lawsuit and settlement opportunity. 

Will your leading mass torts
firms take my case?

Contact us to find out (We’ll get back to you the same day)

"*" indicates required fields

I represent, understand and agree that: 1) I am 18 years of age or older; 2) I have read and agree to Lawsuithelpdesk.com’s Terms of Service, Privacy Policy, that the representations here are Paid Attorney Advertising, and additional legal disclaimers herein (if any); 3) submitting this form does not create an attorney-client relationship; 4) I am not already represented by an attorney for this matter; and 5) I consent to be contacted under the Terms and Conditions of Contact in order to discuss my legal options, so that I may obtain legal representation.

Why Are Valsartan Lawsuits Being Filed?

Valsartan, which is used to treat high blood pressure and heart failure, was recalled in July 2018 by multiple manufacturers due to contamination with NDMA and NDEA— two cancer-causing chemicals. In recent years, there has been a growing concern about the effects of two chemicals – N-Nitrosodimethylamine (NDMA) and N-Nitrosoethanolamine (NDEA) – found in Valsartan. 

Specifically, studies have shown that long-term exposure to these chemicals increase a person’s risk of developing certain types of cancer. A study by a team of researchers from the University of Copenhagen published in 2019, led by Senior Researcher Dr. Henrik Dyssegaard Jensen and Professor of Pharmacology Ranjeet S. Sokhi found that high levels of NDMA and NDEA can increase the risk of several types of cancer, including liver, stomach, bladder and colon cancer. The research looked at levels of two possible carcinogenic impurities (NDMA and NDEA) found in generic Valsartan products manufactured outside Europe. The authors concluded that “long-term exposure to prolonged amounts of NDMA and NDEA should be avoided.” 

As a result, thousands of people who have taken Valsartan may be at risk for developing certain types of cancer, including liver, stomach, bladder, and colorectal cancers. The Valsartan lawsuits accuse the manufacturers of negligence in how the drug was manufactured, failure to warn patients about the dangerous side-effects, and breach of warranty. Plaintiffs are presenting evidence that the drug makers knew or should have known the Valsartan given to patients was contaminated with NDMA and NDEA – which are both carcinogenic – but failed to properly investigate, test, or warn patients and doctors of the risk. As a result, many individuals who’ve taken the tainted Valsartan have been diagnosed with numerous types of cancer.

Generic Valsartan (brand name Diovan) is a widely used medication prescribed by doctors to treat hypertension and congestive heart failure (CHF). It belongs to a class of drugs called angiotensin II receptor blockers (ARBs) and works by relaxing blood vessels, which helps to lower blood pressure and improve blood flow. As an angiotensin II receptor blocker, it helps to relax blood vessels and improve blood flow, thereby increasing longevity after a heart attack. Additionally, its use can help lower blood pressure significantly and prevent stroke as well as kidney malfunctions in diabetes patients. Taken by millions of Americans, Valsartan has become one of the most popular treatments for these conditions.

After learning that Valsartan, the generic version of the drug Diovan, had been contaminated with NDMA, a substance associated to cancer, during the manufacturing process, the US Food and Drug Administration (FDA) ordered the recall of some Valsartan products in July 2018. The government agency said that during manufacture, Valsartan included amounts of the cancer-causing substance N-nitrosodimethylamine (NDMA). NDMA had been used for decades in rocket fuel among other things. Federal “mass tort” cancer claims involving Valsartan pills are centered on this recall and are currently making their way through federal court as MDL (multi-district litigation). Exposure to high amounts of NDMA can cause substantial liver damage and raise the chance of developing liver, gastrointestinal tract, stomach, kidney, and colon cancer. Additional malignancies that may be brought on by Valsartan products  include leukemia, multiple myeloma, non-lymphoma, Hodgkin’s gastric cancer, pancreatic cancer, esophageal cancer, kidney cancer, and prostate cancer.

Liver Cancer: More than any other organ, N-nitrosodimethylamine (NDMA) causes the liver the most damage. Researchers studying cancer use it to make liver tumors in mice despite the fact that it has been known to cause severe, non-cancerous liver problems in humans. Due to the liver’s critical role in maintaining bodily functions, cancer of the liver typically has a bad prognosis. Most liver cancers have a secondary source, which means that they began in another organ or body system before spreading or metastasizing to the liver. As an alternative, primary cancer of the liver develops within the organ and only makes up 2% of cancer cases in the US. Hepatitis, excessive drinking, smoking, and possibly obesity are some of its causes. Men are twice as likely to get primary liver cancer as women. Benign as well as malignant tumors can form in the human liver. Accordingly, symptoms of cancer and non-cancerous conditions may be similar. These are indicators of liver cancer: loss of weight without cause; appetite loss, upper abdominal discomfort; vomiting and nausea; fatigue; skin or eye biliary stains; white, sluggish stools. The usual methods of treating liver cancer are chemotherapy and surgical tumor excision.

Stomach Cancer: Adenocarcinomas are typically easier to cure than liver cancer and have a higher rate of survival, especially when discovered early. Liver cancer frequently develops as a result of GERD and acid reflux. Also, researchers think there is a link between obesity, smoking, and a poor diet and stomach cancer. Other stomach cancer symptoms, like liver cancer symptoms, include: fatigue; following a meal feeling bloated; after consuming a tiny amount of food, feeling full; chronic heartburn; nausea or diarrhea; abdominal pain; and loss of weight. Treatments for stomach cancer are typically suggested by doctors based on the disease’s stage and whether stomach removal surgery, radiation therapy, or chemotherapy is required.

Colorectal Cancer: One of the most prevalent cancers in the US is colon (intestinal) cancer. If detected early, it is treatable and even cured.  Although it can affect anyone at any age, this type of cancer most frequently affects elderly persons. The majority of colon cancers begin as polyps, or growths, on the rectum’s or colon’s inner lining. Precancerous polyps can develop into cancer if they are not removed. A diet strong in fat or red meat, having a family history of the disease, and being over fifty are all risk factors for colon and rectal cancer. To detect and remove polyps, doctors encourage people over fifty to get colonoscopies every five years. Colon cancer signs and symptoms include: alterations to bowel habits; unaccounted-for weight loss; blood in the stool or rectal bleeding; ongoing stomach discomfort. Similarly to stomach cancer, colorectal cancer is treated with chemotherapy, removal of cancerous tumors, and, if necessary, removal of some or all of the colon or rectum.

In July 2018, the European Medicines Agency (EMA) issued a statement warning the public about an increase in NDMA levels found in some batches of Valsartan. Subsequent research established that this was a result of modifications to the production technique utilized by some manufacturers. In order to recall impacted medications and assure safety, the EMA cooperated with local, national, and worldwide regulatory organizations. These businesses are also creating new production techniques to stop the recurrence of such problems. The FDA stated on October 3, 2019, that other products containing Valsartan may contain trace quantities of NDMA over permissible limits as part of the ongoing investigation into valsartan contamination.

The contamination was discovered by Zhejiang Huahai Pharmaceuticals in China which is one of the suppliers for Active Pharmaceutical Ingredients (API) used to make both generic and branded valsartan products. As a result, many companies have recalled their Valsartan products from the market as a precautionary measure.  This raises very serious concerns about carcinogenic side effects for people taking Valsartan. Exposure to high amounts of NDMA can cause substantial liver damage and raise the chance of developing liver, gastrointestinal tract, stomach, kidney, and colon cancer. Prolonged exposure to NDMA can increase the risk of the stomach, small intestine, colorectal, liver, esophagus, pancreas, prostate, as well as leukemia, multiple myeloma, and non-Hodgkin’s lymphoma cancers. 

NDMA also has the potential to be poisonous at high concentrations. After taking significant amounts of NDMA just once, there have been several reported cases of people dying from internal bleeding and serious liver damage. NDMA use at high to moderate levels resulted in significant liver damage after just a few days and cancer after just a few weeks in animal studies. 

According to an examination into the NDMA contamination, Zhejiang Huahai’s alteration to the manufacturing method several years ago was the most likely culprit. As a result, it took some time for the NDMA-tainted Valsartan to be discovered and recalled. This is highly concerning because Valsartan is a long-term daily “maintenance” medication. Because of this, it’s possible that some people have been consuming NDMA once or twice a day for a number of years. This specific kind of long-term, continuous use is the kind of exposure that can result in cancer. 

The Environmental Protection Agency (EPA) also informs that NDMA is not manufactured in its pure form or commercially used in the US, with the exception of research purposes. NDMA was previously utilized in the production of liquid rocket fuel, antioxidants, lubricant additives, and copolymer softeners. Additionally, other side effects, such as nausea, dizziness, and constipation have been reported. 

The Valsartan MDL class action, now pending in New Jersey, is a consolidation of all federal court procedures connected with these complaints. There are currently more than 1200 Valsartan lawsuits pending in the class action lawsuit in federal court. Plaintiffs who took the recalled Valsartan and claim it put them at risk for cancer are suing the defendants in the Valsartan MDL (Valsartan MDL 2875), which is now being heard by Judges Robert B. Kugler, USDJ, and Joel Schneider, USMJ. The plaintiffs assert that the drug companies ought to have been aware of Zhejiang-related drug contamination safety issues prior to the Valsartan recall.

At this point, we are not aware of settlements yet in the Valsartan-related cancer lawsuits. However, this is an ongoing process and settlements could be reached at any time. If a settlement is reached, plaintiffs may receive compensation for medical bills, lost wages due to missed work, and pain and suffering caused by their illnesses. Additionally, punitive damages may also be awarded if it is determined that a drug manufacturer acted with recklessness or willful disregard for consumer safety. Additionally, people who were already taking generic valsartan or another type of ARB before the recall was issued are still able to file a lawsuit against the drug makers even if their specific medication has not been recalled yet. Victims of these contaminated medications should take action to protect their rights as soon as possible.  

How can I tell if I qualify for a Valsartan Lawsuit?

Our lawyers have criteria for whether we would take your case and file a Valsartan lawsuit to obtain a settlement. They base their criteria on the scientific research conducted, their understanding of the relevant courts involved and rulings handed down by judges, exactly what you’d expect from leaders in the field.

If you have taken Valsartan and experienced serious side effects such as cancer, then you may be entitled to significant compensation through a Valsartan lawsuit.

These are the criteria our law firms look for:

  • Usage of the Valsartan in 2015 or later, for one year or longer before the cancer diagnosis;
  • Diagnosis in 2017 or later of any one of these cancers: Stomach, Intestinal, Colorectal, Esophageal, Liver, Prostate (if diagnosed before age 65), Pancreatic, Leukemia, Non-Hodgkins Lymphoma or Multiple Myeloma.
man recovering in hospital who's filed a Valsartan lawsuit
weighing the benefits of Valsartan lawsuit

What are my legal fees, If Your Lawyers Take My Valsartan Case?

Our good news for you is that if you qualify, the legal representation will be entirely contingent fee. That means that all legal costs and expenses are borne by the law firm representing you. You pay nothing out of pocket. The legal costs and expenses come out of the settlement or award you receive. 

Remember, unlike most other mass torts sights, you will be represented by leaders in this field of mass torts, not simply personal injury lawyers or whomever is paying for leads to a marketing firm. 

And what happens if case is not settled or won? You will owe nothing because the risk is entirely borne by law firm representing you.

What can I recover from a Valsartan Lawsuit?

Mass torts cases frequently provide very high dollar settlements, where each plaintiff receives as recovery in the hundreds of thousands or even millions of dollars. 

Having said that, we and our network of law firms have talked to thousands of injured. As we’ve heard time and again, and truly believe — there is no compensation that makes up for a serious injury, period. 

But now that your family is dealing with the pain and suffering, through no fault of your own, you may be entitled to very significant financial compensation. 

To be specific, you would be entitled to recover past, present and future medical and mental health bills, as well as lost wages. Recovery dollars also compensate for non-economic losses, such as past, present and future pain and suffering, loss of consortium (companionship), and emotional distress. 

celebrating a Valsartan Lawsuit settlement
lawyer counseling about Valsartan lawsuit

If I'm qualified for a Valsartan Lawsuit, do I have any obligations to Lawsuit Help Desk? to Your Lawyers?

You have no obligations to us if you’re qualified. If we find that you are qualified, and you wish to proceed with the mass torts firms we have provided for you, the lawyers will discuss the retention agreement with you.

How long do I have to file my Valsartan Lawsuit?

For yours and your family’s sake, act quickly, even if it’s not with us. Why? Statutes of limitations restrictions exacerbated by lagging scientific research may prevent your recovery. Also, if you file late, you may miss important settlement opportunities.  That’s why it’s very important to secure legal representation as soon as possible. In fact, one of our lawyers’ first actions for you will be to check your state’s statute of limitations and repose. 

For every injury, each state has its own statutes of limitations (SOL) and statutes of repose (SOR). These statutes prevent lawsuits from being filed or enforced after preset time limits, which vary from state-to-state. After these periods pass, even if a lawsuit is filed, it will be dismissed and you will collect nothing. 

It may have taken years for scientific research to show a connection between the cause – here, Valsartan usage – and the patient’s symptoms. Research found that Valsartan manufactured between 2015 and 2019 was tainted with the harmful chemical NDMA. Recalls have been issued by the FDA and European health agencies.  

Manufacturers very often settle cases with thousands of defendants at a time; but in order to qualify as a recovery victim, your lawyer must have already filed your lawsuit. Contrary to media outlets, our lawyers have an obligation to the court to conduct their own due diligence – to see whose cases qualify based on leading medical research. Lawsuits that are not brought in good faith risk dismissal and the parties face sanctions. 

lawyers sprinting to file a Valsartan lawsuit
client contacts lawyer about Valsartan lawsuit

What are my next steps for filing and settling a Valsartan Lawsuit?

Reach out to us for a quick assessment of your case. Do it today, do it now! Get peace of mind. 

Also, starting now, save every document our attorneys need as evidence. That includes any prescriptions, receipts, medical bills, medical reports, medical tests and diagnoses, and any other documents linking you to usage of Valsartan and experiencing its side effects.

But don’t worry — our lawyers will reach out to doctors, labs, hospitals and pharmacists should they decide to represent you and your loved ones. Our lawyers will tell you much more when you contact us.

The Lawsuit Help Desk Difference

Unlike most others, we do not act like third party middlemen – instead, we provide you immediate access to top 1%, nationally renowned mass torts attorneys, with deep knowledge in Valsartan litigation. It is these leading lawyers who decide whether your case has merit. We will be forthright and honest with you.

Our mission is to inform the public, and provide direct access to leaders in the world of mass torts. 

We are not that annoying call center. We will respect your time. We will not hand you off, or give you the run around. 

We do not consider ourselves a marketing firm. Do not expect robocalls from us. If you’re emailed, it’s just to provide you helpful information, such as case status and ongoing research; you will not get spammy emails. We are here to help, not badger you.

A key distinction is that we have active attorneys and litigators on our staff. Do you really want advice about a mass tort that’s devastated your loved one’s lives — where settlements in the hundreds of thousands and millions are common — from a marketing or social media expert, a lifestyle coach, a psychologist or an influencer? In other words, we are not parroting talking points: We really know what we’re talking about. 

In fact, Lawsuit Help Desk was founded by Cameron Tousi, a leader in the world of complex litigation. He has received highest distinctions in peer reviews and awards from America’s leading legal publications. If you’d like to speak with Cameron, just let us know, and we’ll make it happen! 

Monthly Status Updates of Valsartan Lawsuits

As of January 2023, In the MDL, there are currently more than 1200 active Valsartan plaintiffs. Thousands of individuals across the United States have filed lawsuits against pharmaceutical companies for their role in manufacturing and distributing tainted valsartan medications. Plaintiffs state that the manufacturers failed to properly test these drugs for contamination with carcinogenic compounds (NDMA or NDEA) prior to distribution. 

The U.S. Food & Drug Administration (FDA) announced the recall of certain valsartan-containing products in July 2018 after discovering that some pills were contaminated with NDMA and NDEA, both known human carcinogens. In a number of states throughout the country, including California, Illinois, New Jersey, New York, Vermont and Washington state — more than 1 million people took recalled valsartan medications.

In January of 2023, hundreds of valsartan lawsuits were filed across the United States, with many more expected to come. The cases are consolidated into a multidistrict litigation (MDL) in the Eastern District of New York before Judge Brian M. Cogan. This MDL is known as In re: Valsartan Products Liability Litigation docket number 1:18-md-02909-BMC— and is used to manage pre-trial proceedings for all federal cases involving similar allegations against the same defendants.

Individuals affected by this recall may be entitled to compensation for medical expenses, lost wages, pain and suffering damages, or any other losses associated with taking valsartan medications and subsequent cancer diagnosis. Attorneys representing plaintiffs in the MDL claim that evidence suggests contaminated drugs were made in China, where manufacturing standards are not as stringent as they are in the United States. 

At this time, no settlement has been announced in the Valsartan litigation. However, similar past cases involving recalled drugs have seen settlements up to several billion dollars. If you or a loved one took a generic valsartan medication and developed any form of cancer after taking it, contact an attorney right away to discuss your eligibility for compensation through a lawsuit filed against the responsible manufacturers. 

The Valsartan litigation is still ongoing and many more lawsuits are expected to be filed before any settlement or resolution is reached. It is important that those affected stay informed about developments pertaining to their case so they can pursue maximum compensation for their losses. 

The defendants in the Valsartan class action MDL filed a request asking the MDL to revisit his earlier decision on the sufficiency of the plaintiffs’ causation evidence in the wake of the recent decision that dismissed all of the Zantac cases. The defendants expected their cases to have a similar outcome to the Zantac decision.

The Valsartan MDL Judge, however, denied this request. Judge Kugler stated in an Order released last week that the scientific concerns in the Zantac lawsuits were very different, and as a result, the decision in that litigation had no bearing on the Valsartan cases. As a result of Judge Kugler’s decision, the Valsartan cases can now proceed to trial.

The news is good. This litigation was hampered by the dismissal of the Zantac NDMA allegations in December. Yes, there are differences in judgement, science, and many other aspects. However, it would be absurd to pretend that the rejection of the Zantac class action lawsuit had no impact on the Valsartan claim. Nevertheless, the first Valsartan trial is on track.

The lawsuits surrounding valsartan continue to be a major concern in the pharmaceutical industry, with several recalls occurring throughout the United States. Numerous valsartan lawsuit claims have been made against certain drug companies following the discovery that their medications contained carcinogens such as N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA). 

In November 2022, plaintiffs from across the country are continuing to battle it out in courtrooms, with hundreds of cases pending. To date, no settlements have been reached and many plaintiffs await their day in court. The results of these trials will set precedent for future cases and provide a greater understanding of the dangers associated with valsartan products. 

As more information is discovered about the side effects of this medication, there are increasing calls for drug companies to be held accountable for releasing dangerous drugs into the market. The Food and Drug Administration (FDA) has set limits on permissible levels of NDMA in all medications and continues to monitor valsartan-containing drugs closely.

As October 2022 begins, Valsartan lawsuits continue to move forward in the legal system. In July of 2018, the FDA recalled several generic versions of Valsartan due to an impurity detected that could cause cancer. Since then, hundreds of individuals have filed suit against drug manufacturers and distributors across the United States claiming that their exposure to contaminated drugs has caused them serious injury or even death. 

Many of these cases are still ongoing with plaintiffs seeking compensation for medical bills, lost wages and other damages incurred as a result of taking the tainted medication. As cases progress through litigation, those affected by the recall have been able to secure settlements from various companies involved in producing or distributing Valsartan products. 

Other affected parties are still attempting to negotiate with companies for compensation and many lawsuits remain pending in courts all over the country. The FDA is also continuing to monitor Valsartan products, as well as its active ingredients, and issue updates when appropriate. As more information becomes available about the long-term health effects of taking contaminated medications such as Valsartan, additional cases may arise in the coming months or years. 

In conclusion, it is clear that Valsartan lawsuits continue to move forward in October 2022 as those affected by contaminated drugs seek justice from pharmaceutical companies involved in the recall. As cases go through the legal process, it is important to stay informed and understand the options available in order to make the best decisions for one’s individual circumstances.

In September of 2022, over two years since the Valsartan recall was issued by various manufacturers, there is still ongoing litigation concerning the drug. Numerous legal actions have been filed by individuals and families of those who had consumed contaminated Valsartan, claiming physical harm from consuming the tainted product, as well as economic loss due to increased medical costs associated with treating related illnesses. 

The latest updates in these lawsuits indicate that a growing number of manufacturers are now facing class action lawsuits for their part in manufacturing and distributing contaminated valsartan products containing NDMA and NDEA. The majority of cases being heard involve claims for personal injury or wrongful death due to consumption of the recalled medication. Plaintiffs state that they were exposed to dangerous levels of NDMA and NDEA due to the Valsartan being contaminated by these chemical compounds. 

In addition, other cases have been filed against manufacturers for economic loss due to increased medical costs associated with treating related illnesses caused by the contaminated valsartan products. Plaintiffs are also suing for damages related to financial losses resulting from having to pay for replacement medication after the original was recalled. 

At this time, thousands of lawsuits have been filed against several different valsartan-producing companies including Teva Pharmaceuticals USA, Inc., Sandoz Inc., Mylan Pharmaceuticals, Ltd., and Zhejiang Huahai Pharmaceuticals Co Ltd. As new developments continue to emerge in these legal actions, it is likely that more class actions and individual lawsuits will be filed as the year goes on. 

Overall, September 2022 has been a busy month for Valsartan litigation. With thousands of individuals filing legal claims against drug manufacturers across the world, there is no doubt that this issue will continue to draw attention as these cases progress in court. It remains to be seen how much compensation claimants may receive for their injuries, medical bills, and other damages related to their exposure to harmful chemical compounds found in contaminated valsartan products.

As of August 2022, the nationwide recall and subsequent lawsuit involving contaminated Valsartan continues to move forward with several interesting developments. An MDL (Multi-District Litigation) against the distributors and manufacturers implicated in the contamination scandal has been established in the U.S. District Court for the Northern District of California. The MDL is currently presided by Judge Haywood S. Gilliam Jr., who has already approved three bellwether trials which are scheduled to begin later this year. 

There have also been a few noteworthy decisions from other courts around the country regarding individual cases brought against these companies by injured parties who had taken contaminated valsartan. Most recently, the U.S. District Court for the Eastern District of New York ruled that plaintiffs who ingested contaminated Valsartan are able to pursue claims under state law regardless of whether they have suffered any identifiable physical injuries as a result. 

Meanwhile, numerous other valsartan lawsuits brought by individuals in various states remain pending in courts around the country. Plaintiffs continue to argue that these companies knew about contamination issues since 2012, yet failed to warn consumers adequately, and seek compensation for medical expenses, lost wages and pain and suffering resulting from their ingestion of contaminated Valsartan. 

It is estimated that currently there are over 500 cases consolidated into the MDL pending before Judge Gilliam as well as hundreds more still awaiting resolution in state and federal courts around the country. 

Therefore, while significant progress has been made since the original valsartan recall announcement, there is still much work to be done before a full resolution of these cases can be achieved. 

As of July 2022, there have been thousands of valsartan lawsuits filed by consumers over the claimed presence of cancer-causing impurities in the product. The underlying issue is that some generic versions of valsartan contained unsafe levels of N-nitrosodimethylamine (NDMA) and N-Nitroso-N-methyl 4-aminobutyric acid (NMBA). Both substances are classified as human carcinogens. 

Patients who may have taken contaminated valsartan to treat high blood pressure or heart failure can now file a lawsuit claiming they developed cancer due to negligence on the part of the manufacturer. The U.S. Judicial Panel on Multidistrict Litigation is currently overseeing all federal lawsuits filed throughout the country. These cases are expected to proceed in one MDL court for pretrial proceedings, including discovery and bellwether trials. 

In addition to filing suit against the valsartan manufacturers, injured parties may also be able to pursue claims against pharmacies or other suppliers who failed to provide adequate warnings about contamination or took inadequate steps to recall the product from shelves when it became apparent that NDMA and NMBA were present at unsafe levels. 

As of July 2022, numerous settlements have been reached between drug makers and plaintiffs throughout the United States, with some cases settling for as much as several million dollars in compensatory damages.

It has been more than four years since the massive Valsartan recall began, leaving many patients with serious health conditions and a lot of questions. Hundreds of lawsuits have been filed in both state and federal courts, claiming that the manufacturers failed to adequately test for carcinogenic contaminants in their products. 

At this time, at least 521 personal injury cases are pending before Judge Freda Wolfson of the U.S District Court for the District of New Jersey. These cases have been consolidated under Multi-District Litigation (MDL) 2875: In Re: Valsartan Products Liability Litigation. The MDL is scheduled to go through several phases, including discovery, bellwether trials and settlement discussions. 

Discovery is currently underway in the MDL and will continue through 2021. During this phase, both sides are gathering evidence to build their cases. Plaintiffs are required to provide information on how they were exposed to the contaminated drugs, their diagnosis of cancer or other injury, and the cost of treatment. Defendants must turn over any documents related to Valsartan manufacturing and testing processes. In addition, both sides may depose witnesses who have knowledge of the product’s history. 

Bellwether trials in the Valsartan MDL could begin as early as 2022 if a settlement is not reached prior to that time. These bellwether trials are intended to give the parties a better idea of how juries may respond to certain arguments or evidence. They are also meant to encourage negotiation of a settlement and bring resolution to many cases without having to go through full trials. 

The manufacturers have begun talks with plaintiffs’ attorneys, as they seek to resolve these cases without going through litigation. While there is no guarantee that Valsartan lawsuits will settle in 2022, it is likely that some form of settlement will be reached before the bellwether trials begin.

As of May 2022, dozens of lawsuits have been filed against the makers and distributors of Valsartan following a massive recall in 2018. The recall was issued after it was discovered that batches of the drug were contaminated with N-nitrosodimethylamine (NDMA), a cancer-causing chemical. Several parties have since joined together to try to hold the manufacturers and distributors accountable for exposing them to this dangerous product. 

Since then, many patients who took Valsartan before or during the recall are now filing lawsuits accusing these companies of negligence and failure to adequately warn consumers about the risks associated with taking the medication. Some plaintiffs state they developed kidney cancer or other types of cancer due to using Valsartan, while others claim they suffered physical side effects but were not aware of the risks. 

In May 2022, many of these lawsuits have been consolidated in multidistrict litigation (MDL) or class action suits. The MDL is currently pending in the U.S. District Court for the Northern District of Illinois and is overseen by Judge Manish S. Shah. As the cases move forward, more plaintiffs may join in and additional defendants may be added to the lawsuit. 

At this time, several companies are named as defendants including Zhejiang Huahai Pharmaceuticals Co., Ltd., Anhui Hongbo Pharmaceutical Company Limited, Wockhardt (UK) Ltd., ALK-Abello Inc., Sandoz Inc., Sanofi-Aventis U.S. LLC, Mylan Pharmaceuticals Inc., and Teva Pharmaceuticals USA Inc., among others. 

The month of April 2022 marks four years since numerous lawsuits have been filed against pharmaceutical companies for the manufacturing and distribution of medication containing contaminated valsartan. This heart medication, which is primarily used to treat high blood pressure and heart failure, was found to contain carcinogenic compounds linked to cancer. As a result, thousands of individuals have lodged complaints against drug makers Teva Pharmaceuticals (Teva), Solco Healthcare LLC (Solco), and Mylan Pharmaceuticals Inc. (Mylan) in an effort to seek damages resulting from their cancers caused by contaminated valsartan medication. 

As of April 2022, the litigation has reached a critical juncture. Over 3,500 valsartan lawsuits have been consolidated into multidistrict litigation (MDL) in New Jersey; however, none of the cases have reached a full trial as yet. With hundreds of new complaints filed each month, the MDL continues to grow and is expected to become even larger in the coming months. 

This April also saw two major developments with regards to valsartan litigation. In particular, on April 7th 2022, Teva Pharmaceuticals rejected claims made by plaintiffs’ lawyers that their drugs contained NDMA at “unreasonably dangerous” levels and argued that they should not be held liable for any damages caused by these medications containing NDMA levels below those set by regulatory bodies. On the same day, Mylan Pharmaceuticals also released a statement claiming that the company was not responsible for selling contaminated valsartan medication and denied any liability.

Despite these developments, it is important to note that patients affected by cancer due to the ingestion of tainted valsartan medication may still be eligible to receive compensation through product liability claims or individual lawsuits.

As of March 2022, numerous lawsuits have been filed against the manufacturers of valsartan, an angiotensin II receptor blocker used to treat hypertension and heart failure. The drug has been linked to various cancer types in patients. The lawsuits claim that the manufacturers knew about a cancer-causing impurity in their products but failed to alert consumers or recall the medications. 

In July 2018, a nationwide recall was issued due to the presence of N-nitrosamines impurities found in some valsartan medications. These contaminants are known carcinogens and can increase one’s risk of developing serious cancers such as liver, stomach, bladder and colorectal cancers. Following this announcement, thousands of individuals have filed lawsuits against the drug’s manufacturers, seeking compensation for medical bills and damages. 

In March 2022, one of the most recent developments in these cases is that several state attorneys general have raised awareness on cancer risks associated with taking valsartan medications and urged patients to take steps to protect themselves. Furthermore, many individuals have joined a nationwide class action lawsuit against the manufacturer of valsartan products sold under various brand names. This class action suit claims that the defendants did not adequately warn consumers about the risk of cancer due to contaminants present in their medication.

Additionally, it was announced this month that some states are proposing legislation that would require drug makers to disclose information about any harmful impurities in medications as soon as possible. This proposed legislation is aiming to ensure that individuals are aware of any health risks associated with their medications, and it could have a major impact on future valsartan cases if passed. 

With the legal landscape constantly changing in regards to these lawsuits, victims and their families need experienced attorneys to protect them against negligent manufacturers. If you or someone you know was diagnosed with cancer after taking valsartan, contact an attorney as soon as possible for help filing a claim. You may be eligible to receive compensation for medical bills, pain and suffering and more. 

Overall, there have been numerous developments in the valsartan lawsuits this month and many more expected in the coming months as this class action lawsuit moves forward. It is important for those affected by the recall to stay up to date on all news related to these cases. 

In February 2022, over 8,400 valsartan lawsuits remain unresolved across the United States. During this month, more than 800 new cases were added to state court dockets, while hundreds of other cases were referred to multidistrict litigation in New Jersey. On February 3rd, the U.S. Judicial Panel on Multidistrict Litigation (JPML) transferred 147 cases to the District Court of New Jersey for coordinated pre-trial proceedings. 

The JPML also decided that all claims made against Zhejiang Huahai Pharmaceuticals – a Chinese manufacturer who produced contaminated batches of valsartan – should be consolidated into one proceeding in Pennsylvania state court. The first bellwether trial is expected to begin sometime in 2022 and will help determine appropriate compensation for injured patients and their families. 

Meanwhile, Canadian courts are still mediating and settling multiple class action lawsuits regarding valsartan contamination. On February 27th, GlaxoSmithKline agreed to a $7 million settlement with plaintiffs in Alberta and British Columbia who had suffered harm due to taking contaminated medication.

Since the 2018 recall of valsartan, a generic medication used to treat high blood pressure and heart failure, thousands of individuals have filed lawsuits against drug companies for failing to adequately test their products. In January of 2022, the litigation involving this dangerous and defective drug continues. 

At least five Plaintiffs have died since filing their lawsuits in relation to injuries caused by tainted valsartan products that were contaminated with carcinogenic impurities. Plaintiffs claim that pharmaceutical companies were aware of the contamination but did not adequately warn consumers about the risks associated with taking these drugs. This resulted in many people having unknowingly taken medications containing NDMA or NDEA, both cancer-causing compounds.

A recent Ohio court ruling allowed two valsartan lawsuits to proceed, leading to the possibility that these cases may be eligible for trial in 2022. A federal judge granted motions to move forward with an individual Plaintiff’s claims against both Watson Laboratories and Indian drugmaker Dr. Reddy’s Laboratories Ltd., despite the companies arguing that their respective drugs contained only trace amounts of NDMA or NDEA. The court decisions indicate that Defendants must prove each Plaintiff was not exposed to a carcinogenic level of NDMA or NDEA before any defense can be considered, furthering victims’ chances of successfully litigating their claims. 

In January 2022, more than 5,200 valsartan lawsuits were filed in Multidistrict Litigation (MDL) as part of the ongoing litigation process. Additionally, there are at least another 1,000 individual claims that have been or are currently being litigated in state courts across the country. 

The MDL is now hearing a series of bellwether trials which will help to determine how juries may respond to evidence presented against valsartan makers. The first trial began on November 2nd and was scheduled to conclude by Christmas Day. No verdict has yet been issued by the jury but it is expected to be decided within weeks. Subsequent trials will commence if both parties agree, so it is possible that more than one verdict could come down as early as 2021. 

The settlement process for valsartan cases is also ongoing, with Plaintiffs and Defendants reaching agreements in several of the claims already filed. A $300 million dollar fund was recently established to provide compensation for those injured by valsartan products and claimants are now able to submit filings for reimbursement. However, it is not yet known when payments will be disbursed to successful applicants or how much they may receive in compensation. 

As of January 2022, the future of valsartan litigation remains uncertain but progress has been made towards holding accountable those responsible for this faulty drug product. Victims and their families continue to suffer physically and emotionally from the health effects caused by contaminated medications, with many still awaiting justice in the form of a court decision or settlement. Those affected are encouraged to contact an experienced attorney for assistance with their claim.

PAID ATTORNEY ADVERTISEMENT: This Website is a group advertisement. It is not a lawyer referral service. Lawsuithelpdesk.com is owned and operated by Awon Holdings LLC and is not a law firm. We connect people to legal service and there is no charge to be connected with an attorney. You are under no obligation to retain any services of those connected through our website. We try our best to keep things fair and balanced to help you make the best choice for you. This information does not constitute legal or medical advice and it should not be relied upon as such. Results are not guaranteed and past performance is not an indication of future success. Always consult with your doctor before modifying your medication or regular medical regimen.

Copyright © 2023 www.lawsuithelpdesk.com - All Rights Reserved